Sutent and Second primary malignancy - a phase IV clinical study of FDA data

Summary:

Second primary malignancy is reported as a side effect among people who take Sutent (sunitinib malate), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Afinitor, and have Metastatic renal cell carcinoma.

The phase IV clinical study analyzes which people have Second primary malignancy when taking Sutent. It is created by eHealthMe based on reports of 44,359 people who have side effects when taking Sutent from the FDA, and is updated regularly.

What is Sutent?

Sutent has active ingredients of sunitinib malate. It is often used in renal cell carcinoma. eHealthMe is studying from 44,554 Sutent users. Check the latest studies of Sutent.

What is Second primary malignancy?

Second primary malignancy (after getting cure a cancer, a new cancer development) is found to be associated with 538 drugs and 467 conditions by eHealthMe. Check the latest studies of Second primary malignancy.

On Jul, 24, 2026

44,359 people reported to have side effects when taking Sutent.
Among them, 337 people (0.76%) have Second primary malignancy.

Could Sutent cause Second primary malignancy?

Among these 337 people:

How long have people been on Sutent when they have Second primary malignancy? *

Click here to view more results

What is the gender of people who have Second primary malignancy when taking Sutent? *

Click here to view

What is the age of people who have Second primary malignancy when taking Sutent? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Sutent and have Second primary malignancy?

- Check whether Second primary malignancy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sutent:

Sutent (44,554 reports)

Second primary malignancy treatments and more:

Second primary malignancy (9,955 reports)

How severe was Second primary malignancy and when was it recovered:

Second primary malignancy in Sutent

Expand to all the drugs that have ingredients of sunitinib malate:

Second primary malignancy and drugs with ingredients of sunitinib malate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Sutent:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Second primary malignancy:

Second primary malignancy (538 drugs)

Browse all the conditions that are associated with Second primary malignancy:

Second primary malignancy (467 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sunitinib malate (the active ingredients of Sutent) and Sutent (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.